

CAR-T THERAPY USES HUMAN LYMPHOCYTES TO REPROGRAM THEM AGAINST TUMOR CELLS.

The method is innovative and gives a chance for life to patients c with leukemia and lymphomas, in the treatment of which all standard protocols have been exhausted.

In 2017, the CAR-T therapy method was named the main achievement of the year in the USA. At the same time, the FDA registered an anti-CD19 CAR-T cell product for treating leukemia and later lymphoma (under the trade name "Kymriah"). The cost of treatment using the new technology was more than \$500,000 per injection!

Employees of the Center for Pediatric Oncology, Hematology, and Immunology continued to work on the development of technology for obtaining a cell product and clinical protocols for managing patients. The goal is to reduce toxicity and increase survival. It is also essential to reduce the cost to make the technology more accessible.



CONTACT US

+375 29 838-40-46
+375 17 287-10-05

ONCOLOGY.BY

CENTER FOR PEDIATRIC ONCOLOGY,
HEMATOLOGY, AND IMMUNOLOGY

CAR-T THERAPY

FOR B-CELL LEUKEMIAS AND
LYMPHOMAS

CAR-T THERAPY


ONE MORE CHANCE

Conservative therapies used at the **Center for Pediatric Oncology, Hematology, and Immunology** can cure acute lymphoblastic leukemia in most children: overall survival reaches 94%.

According to these indicators, Belarus is among the best countries in the world.

Unfortunately, some patients experience relapses of the disease, some of which are not amenable to standard protocol methods of treatment.

In such chemoresistant patients, for whom all standard protocol treatment methods have been exhausted, another chance has appeared - CAR-T therapy.



PRINCIPLE OF THE METHOD

T-lymphocytes are isolated from the patient's blood and placed in a medium for division. Then, a chimeric receptor, CAR, is artificially delivered to the cells, recognizing a protein on the membrane of leukemia or lymphoma tumor cells. The thus modified lymphocytes are then returned to the patient by intravenous infusion

CAR-T CELL FUNCTION

CAR-T-lymphocytes circulate in the patient's blood and bone marrow, finding and killing all tumor cells. As a result, the patient achieves remission for cancer and B-cell aplasia, which is not dangerous and can be replaced by intravenous immunoglobulin.

TREATMENT COST

The cost of CAR-T therapy for foreign citizens is US\$ 55,000; however, it is not fixed and may vary depending on the severity of the patient's condition and the volume of the required examination. In the event of a reduction in the cost of treatment, the Center guarantees a refund.

GET A CONSULTATION

You can ask questions and send medical documentation by e-mail: oncology.by@gmail.com with the obligatory indication of the phone number for feedback and citizenship (residence permit in the Republic of Belarus) of the patient. A complete list of services can be found on the website: oncology.by.